STALICLA is a biopharmaceutical company focused on serving patients with neurodevelopmental conditions, particularly autism spectrum disorder. The company has brought together a team of seasoned drug developers, medical professionals, and computational systems biologists. Its proprietary technology, DEPI, identifies distinct patient subgroups within the diverse neurodevelopmental disorder population and customizes treatments. This supports the advancement of its drug discovery platform and pipeline development.